Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 6.74% is 134% above its 5-year average of -19.75%, near the high end of its 5-year range (-67.53%–35.69%).
As of the fiscal period ended Tuesday, June 30, 2026. 199.65% above its 12-month average of -6.77%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 6.74%.
RETURN ON INVESTED CAPITAL (ROIC)
6.74%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-6.77%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-3.52%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-19.75%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-38.71%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+199.65%
CURRENT VS 3Y AVG
+291.63%
CURRENT VS 5Y AVG
+134.13%
CURRENT VS 10Y AVG
+117.41%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
+118.90%
vs the sector median at left
Protagonist Therapeutics, Inc.
Market Cap
$8.92B
Return on Invested Capital (ROIC)
6.74%
TTM Avg
-6.77%
3Y Avg
-3.52%
5Y Avg
-19.75%
Market Cap
$8.93B
Return on Invested Capital (ROIC)
2.56%
TTM Avg
2.83%
3Y Avg
6.99%
5Y Avg
7.71%
Market Cap
$8.97B
Return on Invested Capital (ROIC)
-50.82%
TTM Avg
-63.49%
3Y Avg
-63.78%
5Y Avg
-84.79%
Market Cap
$8.72B
Return on Invested Capital (ROIC)
-22.30%
TTM Avg
-24.81%
3Y Avg
-28.43%
5Y Avg
-24.27%
Market Cap
$8.67B
Return on Invested Capital (ROIC)
-12.12%
TTM Avg
-26.48%
3Y Avg
-28.91%
5Y Avg
-26.88%
Market Cap
$9.21B
Return on Invested Capital (ROIC)
2.56%
TTM Avg
2.83%
3Y Avg
6.99%
5Y Avg
7.71%
Market Cap
$9.33B
Return on Invested Capital (ROIC)
16.04%
TTM Avg
12.65%
3Y Avg
9.01%
5Y Avg
7.29%
Market Cap
$8.38B
Return on Invested Capital (ROIC)
22.98%
TTM Avg
-12.21%
3Y Avg
-17.44%
5Y Avg
-20.18%
Market Cap
$9.63B
Return on Invested Capital (ROIC)
-40.65%
TTM Avg
-24.67%
3Y Avg
-27.62%
5Y Avg
-28.57%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) | $8.92B | 6.74% | -6.77% | -3.52% | -19.75% |
| Bruker Corporation (BRKRP)vs › | $8.93B | 2.56% | 2.83% | 6.99% | 7.71% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | -50.82% | -63.49% | -63.78% | -84.79% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.72B | -22.30% | -24.81% | -28.43% | -24.27% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | -12.12% | -26.48% | -28.91% | -26.88% |
| Bruker Corporation (BRKR)vs › | $9.21B | 2.56% | 2.83% | 6.99% | 7.71% |
| Insulet Corp. (PODD)vs › | $9.33B | 16.04% | 12.65% | 9.01% | 7.29% |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 22.98% | -12.21% | -17.44% | -20.18% |
| Vaxcyte, Inc. (PCVX)vs › | $9.63B | -40.65% | -24.67% | -27.62% | -28.57% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 14.41% | 9.77% | -4.93% | -7.04% |
ROIC
6.7%
ROE
9.8%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | 6.74% |
| 2026-03-31 | -21.49% |
| 2025-12-31 | -25.23% |
| 2025-09-30 | 2.75% |
| 2025-06-30 | 3.40% |
| 2025-03-31 | 3.79% |
| 2024-12-31 | 35.69% |
| 2024-09-30 | 26.32% |
| 2024-06-30 | 26.16% |
| 2024-03-31 | 24.72% |
| 2023-12-31 | -27.82% |
| 2023-09-30 | -50.71% |
| 2023-06-30 | -50.05% |
| 2023-03-31 | -67.53% |
| 2022-12-31 | -60.61% |
| 2022-09-30 | -54.10% |
| 2022-06-30 | -49.70% |
| 2022-03-31 | -40.62% |
| 2021-12-31 | -41.74% |
| 2021-09-30 | -32.23% |
| 2021-06-30 | -22.56% |
| 2021-03-31 | -26.12% |
| 2020-12-31 | -22.70% |
| 2020-09-30 | -35.23% |
| 2020-06-30 | -38.17% |
| 2020-03-31 | -86.85% |
| 2019-12-31 | -67.38% |
| 2019-09-30 | -63.49% |
| 2019-06-30 | -61.73% |
| 2019-03-31 | -45.19% |
| 2018-12-31 | -37.30% |
| 2018-09-30 | -24.34% |
| 2018-06-30 | -23.94% |
| 2018-03-31 | -27.62% |
| 2017-12-31 | -31.27% |
| 2017-09-30 | -78.70% |
| 2017-06-30 | -78.44% |
| 2017-03-31 | -53.27% |
| 2016-12-31 | -37.31% |
| 2016-09-30 | -26.95% |
| 2016-06-30 | -113.46% |
| 2016-03-31 | -69.91% |
| 2015-12-31 | -126.24% |
